PT2281831T - Vacina contra o vírus varicela zoster - Google Patents

Vacina contra o vírus varicela zoster

Info

Publication number
PT2281831T
PT2281831T PT101882561T PT10188256T PT2281831T PT 2281831 T PT2281831 T PT 2281831T PT 101882561 T PT101882561 T PT 101882561T PT 10188256 T PT10188256 T PT 10188256T PT 2281831 T PT2281831 T PT 2281831T
Authority
PT
Portugal
Prior art keywords
virus vaccine
zoster virus
varicella zoster
varicella
vaccine
Prior art date
Application number
PT101882561T
Other languages
English (en)
Inventor
Jules Hanon Emmanuel
Stephenne Jean
Original Assignee
Glaxosmithkline Biologicals Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34430592&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT2281831(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxosmithkline Biologicals Sa filed Critical Glaxosmithkline Biologicals Sa
Publication of PT2281831T publication Critical patent/PT2281831T/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A61K39/25—Varicella-zoster virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16722—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16734—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
PT101882561T 2005-03-03 2006-03-01 Vacina contra o vírus varicela zoster PT2281831T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0504436.7A GB0504436D0 (en) 2005-03-03 2005-03-03 Vaccine

Publications (1)

Publication Number Publication Date
PT2281831T true PT2281831T (pt) 2018-06-15

Family

ID=34430592

Family Applications (4)

Application Number Title Priority Date Filing Date
PT101882561T PT2281831T (pt) 2005-03-03 2006-03-01 Vacina contra o vírus varicela zoster
PT101882157T PT2301955T (pt) 2005-03-03 2006-03-01 Vacina contra o vírus varicela zoster
PT101882140T PT2281830T (pt) 2005-03-03 2006-03-01 Vacina contra o vírus varicela zoster
PT67074468T PT1858917E (pt) 2005-03-03 2006-03-01 Vacina contra o vírus varicela zoster

Family Applications After (3)

Application Number Title Priority Date Filing Date
PT101882157T PT2301955T (pt) 2005-03-03 2006-03-01 Vacina contra o vírus varicela zoster
PT101882140T PT2281830T (pt) 2005-03-03 2006-03-01 Vacina contra o vírus varicela zoster
PT67074468T PT1858917E (pt) 2005-03-03 2006-03-01 Vacina contra o vírus varicela zoster

Country Status (35)

Country Link
US (3) US20080171079A1 (pt)
EP (4) EP1858917B8 (pt)
JP (2) JP5420842B2 (pt)
KR (2) KR101357204B1 (pt)
CN (2) CN103028113B (pt)
AR (2) AR052498A1 (pt)
AU (1) AU2006222225B2 (pt)
BR (1) BRPI0607840B1 (pt)
CA (2) CA2882255C (pt)
CY (5) CY1116108T1 (pt)
DK (4) DK2281830T3 (pt)
EA (1) EA011884B1 (pt)
ES (4) ES2532803T3 (pt)
GB (1) GB0504436D0 (pt)
HK (1) HK1111427A1 (pt)
HR (4) HRP20150142T1 (pt)
HU (4) HUE032544T2 (pt)
IL (1) IL185442A (pt)
LT (4) LT2301955T (pt)
LU (1) LUC00087I2 (pt)
MA (1) MA29714B1 (pt)
MX (2) MX2007010626A (pt)
MY (1) MY148464A (pt)
NL (1) NL300951I2 (pt)
NO (1) NO341841B1 (pt)
NZ (1) NZ561075A (pt)
PE (2) PE20100658A1 (pt)
PL (4) PL1858917T3 (pt)
PT (4) PT2281831T (pt)
SI (4) SI2301955T1 (pt)
TR (2) TR201809393T4 (pt)
TW (1) TWI403517B (pt)
UA (1) UA94900C2 (pt)
WO (1) WO2006094756A2 (pt)
ZA (1) ZA200707144B (pt)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0504436D0 (en) * 2005-03-03 2005-04-06 Glaxosmithkline Biolog Sa Vaccine
TWI457133B (zh) 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
RU2010105858A (ru) * 2007-07-19 2011-08-27 Новавакс, Инк. (Us) Вирусоподобные частицы (vlp) вируса varicella zoster и антигены
FR2952825B1 (fr) 2009-11-24 2012-05-25 Goaster Jacqueline Le Utilisation d'un vaccin contre le virus vzv/hsv3 pour traiter les infections herpetiques par le virus hsv1 et/ou le virus hsv2
ES2770335T3 (es) 2010-07-06 2020-07-01 Glaxosmithkline Biologicals Sa Administración de ARN para desencadenar múltiples vías inmunológicas
PL2590626T3 (pl) 2010-07-06 2016-04-29 Glaxosmithkline Biologicals Sa Liposomy z lipidami o korzystnej wartości pka do dostarczania rna
WO2012006369A2 (en) 2010-07-06 2012-01-12 Novartis Ag Immunisation of large mammals with low doses of rna
UA112970C2 (uk) * 2010-08-05 2016-11-25 Мерк Шарп Енд Доме Корп. Інактивований вірус вітряної віспи, спосіб його одержання і застосування
LT3981427T (lt) 2010-08-31 2022-08-10 Glaxosmithkline Biologicals S.A. Pegilintos liposomos, skirtos imunogeną koduojančios rnr pristatymui
MX363307B (es) 2010-10-11 2019-03-20 Novartis Ag Star Plataformas para suministro de antigenos.
CA2840989A1 (en) 2011-07-06 2013-01-10 Novartis Ag Immunogenic combination compositions and uses thereof
US9849066B2 (en) 2013-04-24 2017-12-26 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
JP2015091794A (ja) * 2013-10-03 2015-05-14 日東電工株式会社 注射ワクチン組成物
JP6499420B2 (ja) * 2014-11-13 2019-04-10 公益財団法人ヒューマンサイエンス振興財団 ワクチン及び感染防御キット
BE1022523B1 (fr) * 2014-12-18 2016-05-20 Glaxosmithkline Biologicals Sa Vaccination
MX2017008055A (es) * 2014-12-18 2017-09-28 Glaxosmithkline Biologicals Sa Vacunacion.
CA3002912A1 (en) * 2015-10-22 2017-04-27 Modernatx, Inc. Nucleic acid vaccines for varicella zoster virus (vzv)
EP4011451A1 (en) 2015-10-22 2022-06-15 ModernaTX, Inc. Metapneumovirus mrna vaccines
IL286493B (en) 2015-11-06 2022-07-01 Memorial Sloan Kettering Cancer Center Triterpene saponin analogs, methods for their production, preparations containing them and their uses
US10925958B2 (en) 2016-11-11 2021-02-23 Modernatx, Inc. Influenza vaccine
WO2018097642A1 (ko) * 2016-11-25 2018-05-31 재단법인 목암생명과학연구소 바리셀라 조스터 바이러스 백신
EP3545972A4 (en) * 2016-11-25 2020-05-13 Mogam Institute For Biomedical Research VARICELLA AND ZONA VIRUS VACCINE
CN107022559A (zh) * 2016-12-08 2017-08-08 长春祈健生物制品有限公司 一种水痘‑带状疱疹病毒糖蛋白e胞外区蛋白的制备方法
GB201621686D0 (en) 2016-12-20 2017-02-01 Glaxosmithkline Biologicals Sa Novel methods for inducing an immune response
AU2017389221B2 (en) * 2016-12-26 2020-10-08 Access To Advanced Health Institute Herpes zoster vaccine composition
CN108727503A (zh) * 2017-04-18 2018-11-02 武汉博沃生物科技有限公司 VZV重组gE-鞭毛素融合蛋白及其制备方法和应用
JP7177082B2 (ja) * 2017-04-25 2022-11-22 アジュバンス・テクノロジーズ・インコーポレーテッド トリテルペンサポニン類似物
CA3061205A1 (en) * 2017-04-25 2018-11-01 Adjuvance Technologies, Inc. Triterpene saponin analogues
WO2018198085A1 (en) 2017-04-28 2018-11-01 Glaxosmithkline Biologicals Sa Vaccination
GB201707700D0 (en) 2017-05-12 2017-06-28 Glaxosmithkline Biologicals Sa Dried composition
BR112019025193A2 (pt) 2017-05-30 2020-06-23 Glaxosmithkline Biologicals S.A. Métodos de fabricação de um adjuvante lipossomal, de fabricação de um concentrado lipossomal, para a preparação de uma composição imunogênica com adjuvante e para a preparação de uma solução, adjuvante lipossomal, composição imunogênica com adjuvante, e, solução
CA3075822A1 (en) 2017-10-16 2019-04-25 Adjuvance Technologies, Inc. Triterpene saponin analogues
CN111670044A (zh) 2017-12-01 2020-09-15 葛兰素史密丝克莱恩生物有限公司 皂苷纯化
CN108315344A (zh) * 2018-02-14 2018-07-24 武汉博沃生物科技有限公司 Vzv糖蛋白e基因表达载体及其重组酵母菌株与应用
KR102337922B1 (ko) 2018-04-19 2021-12-09 가천대학교 산학협력단 담팔수 추출물에서 분리한 화합물을 유효성분으로 함유하는 수두-대상포진 바이러스 억제용 약학적 조성물
KR20190121956A (ko) 2018-04-19 2019-10-29 가천대학교 산학협력단 담팔수 추출물에서 분리한 화합물을 유효성분으로 함유하는 수두-대상포진 바이러스 억제용 약학적 조성물
WO2019225962A1 (ko) 2018-05-23 2019-11-28 재단법인 목암생명과학연구소 바리셀라 조스터 바이러스의 항원 변이체 및 이의 용도
WO2020030572A1 (en) 2018-08-07 2020-02-13 Glaxosmithkline Biologicals Sa Processes and vaccines
CN108992667A (zh) * 2018-08-09 2018-12-14 安徽智飞龙科马生物制药有限公司 一种带状疱疹疫苗及其制备方法、应用
KR102270048B1 (ko) * 2020-07-10 2021-06-28 주식회사 녹십자 바리셀라 조스터 바이러스 표면 단백질 항원의 생산 방법
EP3868399A4 (en) * 2018-09-27 2022-07-20 Bravovax Co., Ltd. IMMUNE COMPOSITION, METHOD FOR PREPARATION AND ASSOCIATED APPLICATION
US20220339282A1 (en) 2018-11-29 2022-10-27 Glaxosmithkline Biologicals Sa Methods for manufacturing an adjuvant
CN109602901B (zh) * 2019-01-08 2022-05-27 成都迈科康生物科技有限公司 一种带状疱疹病毒疫苗及其制备方法和应用
CN114080393A (zh) 2019-06-05 2022-02-22 葛兰素史克生物有限公司 皂苷纯化
CN112142828B (zh) * 2019-06-28 2022-02-01 怡道生物科技(苏州)有限公司 一种gE基因及表达该基因的载体
JP2023506440A (ja) * 2019-12-13 2023-02-16 遠大賽威信生命科学（南京）有限公司 免疫刺激性組成物及びその用途
KR20210110242A (ko) * 2020-02-28 2021-09-07 (주)셀트리온 수두 대상포진 바이러스 융합 단백질 및 이를 포함하는 면역원성 조성물
US20230287038A1 (en) 2020-08-07 2023-09-14 Access To Advanced Health Institute Purified saponins and chromatographic process for purification of same
US20240033346A1 (en) * 2020-09-11 2024-02-01 Eubiologics Co., Ltd. Vaccine composition for chickenpox or varicella zoster and method of using same
RU2750818C1 (ru) * 2020-11-19 2021-07-05 Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт вакцин и сывороток им. И.И. Мечникова" (ФГБНУ НИИВС им. И.И. Мечникова Вирусный штамм для получения аттенуированной живой культуральной вакцины для профилактики и лечения опоясывающего герпеса для взрослого населения
WO2023056912A1 (en) * 2021-10-08 2023-04-13 Suzhou Abogen Biosciences Co., Ltd. Nucleic acid vaccines for vzv
WO2023064612A2 (en) 2021-10-15 2023-04-20 BioNTech SE Pharmaceutical compositions for delivery of viral antigens and related methods
WO2023096963A1 (en) 2021-11-24 2023-06-01 Flagship Pioneering Innovations Vi, Llc Varicella-zoster virus immunogen compositions and their uses
CN116350770A (zh) * 2021-12-28 2023-06-30 成都迈科康生物科技有限公司 一种带状疱疹疫苗制剂及其制备方法
WO2024017827A1 (en) 2022-07-19 2024-01-25 Glaxosmithkline Biologicals Sa Continuous process for vaccine production

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5341202B2 (pt) 1974-03-12 1978-11-01
US4436727A (en) 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
SE8205892D0 (sv) 1982-10-18 1982-10-18 Bror Morein Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin
US4769239A (en) 1984-08-21 1988-09-06 Merck & Co., Inc. Vaccine against varicella-zoster virus
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
CA1331443C (en) 1987-05-29 1994-08-16 Charlotte A. Kensil Saponin adjuvant
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
ATE119939T1 (de) 1989-06-27 1995-04-15 Smithkline Beecham Biolog Verbindungen.
EP0468520A3 (en) 1990-07-27 1992-07-01 Mitsui Toatsu Chemicals, Inc. Immunostimulatory remedies containing palindromic dna sequences
CA2085827C (en) 1991-12-23 2003-10-14 Lucas A. T. Hilgers Adjuvant composition containing synthetic hydrophobic lipopolysaccharide
KR100278157B1 (ko) * 1992-06-25 2001-01-15 장 스테판느 보조약을 함유하는 백신 조성물
CA2139515C (en) 1992-07-17 2008-12-23 Gary B. Calandra Method for preventing zoster or alleviating varicella related post-herpetic neuralgia
DK0812593T4 (da) 1993-03-23 2008-05-13 Smithkline Beecham Biolog Vaccinepræparater indeholdende 3-O-deacyleret monophosphoryllipid-A
US5976552A (en) * 1995-04-28 1999-11-02 Protein Sciences Corporation Virus vaccines
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
EP0772619B2 (en) 1994-07-15 2010-12-08 The University of Iowa Research Foundation Immunomodulatory oligonucleotides
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
JP4373495B2 (ja) * 1995-03-23 2009-11-25 イミュネックス・コーポレーション Ｉｌ−１７受容体
UA56132C2 (uk) * 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
US6846489B1 (en) 1995-04-25 2005-01-25 Smithkline Beecham Biologicals S.A. Vaccines containing a saponin and a sterol
KR0177323B1 (ko) * 1996-02-16 1999-04-01 성재갑 바이러스 백신 생산에 유용한 사람 이배체 폐세포 및 이를 이용한 수두 백신의 제조방법
PT971739E (pt) 1997-04-01 2004-12-31 Corixa Corp Composicoes aquosas de adjuvante imunologico de monofosforil lipido a
GB9718901D0 (en) 1997-09-05 1997-11-12 Smithkline Beecham Biolog Vaccine
WO1999011241A1 (en) 1997-09-05 1999-03-11 Smithkline Beecham Biologicals S.A. Oil in water emulsions containing saponins
GB9901254D0 (en) * 1999-01-20 1999-03-10 Smithkline Beecham Biolog Vaccines
NZ525320A (en) * 2000-10-18 2004-10-29 Glaxosmithkline Biolog S Combinations of immunostimulatory oligonucleotides (CpG), saponin and optionally lipopolysaccharides as potent vaccine adjuvants
GB0504436D0 (en) * 2005-03-03 2005-04-06 Glaxosmithkline Biolog Sa Vaccine

Also Published As

Publication number Publication date
PT2281830T (pt) 2017-02-24
CY2018025I2 (el) 2018-12-12
TR201809397T4 (tr) 2018-07-23
UA94900C2 (uk) 2011-06-25
JP5420842B2 (ja) 2014-02-19
HRP20180988T1 (hr) 2018-08-10
LT2281830T (lt) 2017-02-10
SI2281830T1 (sl) 2017-03-31
NO341841B1 (no) 2018-02-05
HRP20180989T1 (hr) 2018-08-10
EA200701632A1 (ru) 2008-02-28
PL2281831T3 (pl) 2018-08-31
PL1858917T3 (pl) 2015-05-29
MX2007010626A (es) 2007-10-16
KR20070110413A (ko) 2007-11-16
MA29714B1 (fr) 2008-09-01
SI1858917T1 (sl) 2015-03-31
TW200643028A (en) 2006-12-16
ES2675055T3 (es) 2018-07-06
LT2281831T (lt) 2018-07-10
EP2281831A2 (en) 2011-02-09
CY2018025I1 (el) 2018-12-12
DK2281831T3 (en) 2018-06-14
PE20061287A1 (es) 2006-12-07
CN101189254B (zh) 2013-05-22
HRP20170081T1 (hr) 2017-03-24
TR201809393T4 (tr) 2018-07-23
WO2006094756A3 (en) 2007-02-15
HK1111427A1 (en) 2008-08-08
CN101189254A (zh) 2008-05-28
CN103028113B (zh) 2015-05-20
HUE032544T2 (en) 2017-10-30
SI2281831T1 (en) 2018-07-31
IL185442A (en) 2013-07-31
NZ561075A (en) 2009-06-26
AR107285A2 (es) 2018-04-18
PL2301955T3 (pl) 2018-08-31
EP1858917B1 (en) 2014-12-24
US20110045059A1 (en) 2011-02-24
PE20100658A1 (es) 2010-10-23
NO20074392L (no) 2007-11-27
NL300951I1 (nl) 2018-09-26
ES2532803T3 (es) 2015-03-31
EP2281830A2 (en) 2011-02-09
TWI403517B (zh) 2013-08-01
ES2618037T3 (es) 2017-06-20
CN103028113A (zh) 2013-04-10
GB0504436D0 (en) 2005-04-06
HUE038467T2 (hu) 2018-10-29
DK1858917T3 (da) 2015-02-02
SI2301955T1 (en) 2018-07-31
AR052498A1 (es) 2007-03-21
EP2281831B1 (en) 2018-04-18
EP2281830B1 (en) 2016-12-21
EP1858917A2 (en) 2007-11-28
EP2281830A3 (en) 2012-01-25
PL2281830T3 (pl) 2017-06-30
MY148464A (en) 2013-04-30
LTC2281831I2 (lt) 2020-08-25
ZA200707144B (en) 2009-11-25
JP2008531637A (ja) 2008-08-14
KR101357204B1 (ko) 2014-02-06
AU2006222225A1 (en) 2006-09-14
CA2882255A1 (en) 2006-09-14
US20110104260A1 (en) 2011-05-05
HUE038468T2 (hu) 2018-10-29
PT2301955T (pt) 2018-06-18
EP2281831A3 (en) 2011-11-16
DK2301955T3 (en) 2018-06-14
DK2281830T3 (en) 2017-03-20
ES2675054T3 (es) 2018-07-06
KR20140006115A (ko) 2014-01-15
EP2301955A3 (en) 2011-11-16
JP5840167B2 (ja) 2016-01-06
LUC00087I2 (pt) 2018-11-26
CA2600905A1 (en) 2006-09-14
EP2301955B1 (en) 2018-04-18
EP2301955A2 (en) 2011-03-30
CY1120347T1 (el) 2018-12-12
EP1858917B8 (en) 2015-05-06
HRP20150142T1 (hr) 2015-05-22
CA2600905C (en) 2015-05-05
PT1858917E (pt) 2015-02-24
BRPI0607840A2 (pt) 2009-06-13
HUS1800038I1 (hu) 2018-10-29
EA011884B1 (ru) 2009-06-30
CA2882255C (en) 2018-03-27
US7939084B1 (en) 2011-05-10
BRPI0607840B1 (pt) 2021-06-29
LTPA2018012I1 (lt) 2018-11-12
US20080171079A1 (en) 2008-07-17
CY1121211T1 (el) 2020-05-29
LT2301955T (lt) 2018-07-10
MX346865B (es) 2017-04-04
NL300951I2 (nl) 2020-08-31
CY1118629T1 (el) 2017-07-12
AU2006222225B2 (en) 2012-08-16
JP2013144710A (ja) 2013-07-25
WO2006094756A2 (en) 2006-09-14
CY1116108T1 (el) 2017-02-08
IL185442A0 (en) 2008-01-06

Similar Documents

Publication Publication Date Title
HUS1800038I1 (hu) Varicella zoster vírus oltóanyag
IL192084A0 (en) Vaccine
ZA200906115B (en) Antibodies specific for Varicella Zoster Virus
GB0524408D0 (en) Vaccines
GB0515135D0 (en) Vaccine
ZA200709207B (en) Vaccine
GB0516944D0 (en) Vaccine
GB0810662D0 (en) Vaccine
ZA200709210B (en) Vaccine
GB0709408D0 (en) Anti-col herpes virus compounds
GB0526412D0 (en) Vaccine
IL186586A0 (en) Vaccine
GB0513194D0 (en) Vaccine
GB0513189D0 (en) Vaccine
IL186591A0 (en) Vaccine
GB0503000D0 (en) Anti-atheroma vaccine
GB0526232D0 (en) Vaccine
GB0514021D0 (en) Vaccine
GB0523445D0 (en) Vaccine
GB0509010D0 (en) Vaccine
GB0515242D0 (en) Vaccine
GB0511475D0 (en) Vaccine